Bloomberg Anywhere Remote Login Bloomberg Terminal Request a Demo

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us

Magazine

Table: Merck's Mounting Woes


PATENT EXPIRATIONS

Patents have expired or will shortly on several big sellers, including the blockbuster hypertension drug Prinivil. When patents go, cheap generic knockoffs rapidly kill sales of the original.

VIOXX HEADACHES

Growth of the blockbuster painkiller Vioxx has slowed this year after a study raised questions about whether the drug poses a cardiovascular risk.

GAPS IN THE PIPELINE

Merck's pipeline of new drugs for the next few years is thin, so investors are anxiously awaiting the company's Dec. 11 analysts meeting. If Merck doesn't outline some potential big sellers, pressure may mount for the drugmaker to make an acquisition or sign a drug-licensing deal.


LIMITED-TIME OFFER SUBSCRIBE NOW
 
blog comments powered by Disqus